Skip to main content
Toggle navigation
Login
Search
Home
Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Browse by Poster Title
Browse by Poster Title
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
#
Sort by
Title
T
P 89
TARGETED THERAPY OF MET, TYROSINE KINASE RECEPTOR, IN PEDIATRIC HIGH-GRADE OSTEOSARCOMAS : A NEW WAY TO TREAT PATIENTS ?
Favorite
P 90
TARGETING HIGH RISK MYC- AMPLIFIED OSTEOSARCOMA BY AURORA KINASE INHIBITOR--RESULT FROM A NGS BASED UMBRELLA TRIAL
Favorite
P 136
TARGETING MIR-138-5P TO TREAT DEDIFFERENTIATED LIPOSARCOMA
Favorite
P 137
TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Favorite
P 414
TENOSYNOVIAL GIANT CELL TUMOR IN CHILDREN: INTERIM RESULTS FROM A PHASE 1 STUDY OF TURALIO®
Favorite
P 340
THE DNA MINOR GROOVE BINDING AGENTS ECUBECTEDIN AND PM54 DEMONSTRATE ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA
Favorite
P 91
THE EFFECT OF CHEMOTHERAPY AND SURGERY TIMING ON MORTALITY IN THE TREATMENT OF UPPER AND LOWER EXTREMITY OSTEOSARCOMA: A DATABASE STUDY
Favorite
P 341
THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Favorite
P 246
THE GENOMIC AND IMMUNE LANDSCAPE OF LIPOSARCOMA AND ITS SUBTYPES
Favorite
P 92
THE IMPACT OF CHONDROSARCOMA WITH POSITIVE MARGINS AND EXTRAOSSEOUS EXTENSION ON PATIENT OUTCOMES
Favorite
P 28
THE INFLUENCE OF MARGINS ON OUTCOME IN CUTANEOUS LOCATED SOFT TISSUE SARCOMAS IN THE HEAD AND NECK
Favorite
P 93
THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA
Favorite
P 247
THE REAL-WORLD EFFICACY OF IMMUNE CHECKPOINT INHIBITORS WITH CONCURRENT RADIATION OR SURGERY IN MULTIMODAL TREATMENT OF SOFT TISSUE SARCOMAS: A RETROSPECTIVE STUDY
Favorite
P 388
THE ROAD TO CURATIVE SURGERY IN RETROPERITONEAL SOFT TISSUE SARCOMA: A DIFFERENT PATH IN THE ELDERLY?
Favorite
P 94
THE ROLE OF CMYC AMPLIFICATION VERSUS CMYC PROTEIN EXPRESSION AS A PROGNOSTIC BIOMARKER IN OSTEOSARCOMA
Favorite
P 342
THE ROLE OF MYELOPEROXIDASE IN SARCOMA TREATMENT
Favorite
P 389
THE ROLE OF NUTRITIONAL STATUS ON POSTOPERATIVE AND ONCOLOGICAL OUTCOMES IN RETROPERITONEAL SARCOMA
Favorite
P 432
THE ROLE OF SYSTEMIC TREATMENT IN ADVANCED SOLITARY FIBROUS TUMORS: EXPERIENCE AT A REFERRAL CENTER.
Favorite
P 319
THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
Favorite
P 95
THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN PATIENTS WITH CHONDROSARCOMA: UPDATED RESULTS FROM A PHASE 1 STUDY
Favorite
P 117
THE TUMOR IMMUNE MICROENVIRONMENT OF DEDIFFERENTIATED SARCOMAS: DIGITAL SPATIAL PROFILING SHOWS IMMUNE TRANSCRIPTIONAL DIFFERENCES BETWEEN DEDIFFERENTIATED LIPOSARCOMA AND CHONDROSARCOMA
Favorite
P 281
THE UTILITY OF INTRAOPERATIVE MARROW MARGIN FROZEN SECTION IN EXTREMITY BONE SARCOMA RESECTION
Favorite
P 343
TLE1 DISRUPTION DOES NOT IMPEDE SYNOVIAL SARCOMAGENESIS
Favorite
P 248
TNT: A PHASE 2 STUDY USING TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN FOR ADVANCED LEIOMYOSARCOMA AND LIPOSARCOMA (NCT # 03886311)
Favorite
P 415
TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Favorite
P 96
TRACP-5B AS A BIOMARKER FOR LONG-TERM DENOSUMAB TREATMENT OF UNRESECTABLE GIANT CELL TUMOR OF BONE
Favorite
P 344
TRANSCRIPTOMIC ANALYSIS OF DESMOID TUMOR RESPONSE TO NIROGACESTAT: NOVEL MECHANISMS OF RESISTANCE?
Favorite
P 345
TRANSCRIPTOMIC AND PHENOTYPIC CHARACTERIZATION OF AN IMMUNOCOMPETENT LEIOMYOSARCOMA MOUSE MODEL.
Favorite
P 97
TRANSCRIPTOMICS REVEALS THAT OVEREXPRESSION OF LNCRNA HOTTIP REGULATES PKC PROTEIN ACTIVATION OF THE RAP1 SIGNALING PATHWAY FOR SYNOVIAL SARCOMA CELL PROGRESSION
Favorite
P 360
TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
Favorite
P 416
TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Favorite
P 249
TUMOR CELL DISAPPEARANCE FOLLOWING COVID-19 INFECTION IN A PATIENT WITH PLEOMORPHIC SPINDLE CELL SARCOMA: A CASE REPORT
Favorite
P 433
TUMOR HYPOXIA AND THE RISK OF METASTASIS IN HIGH-RISK LOCALIZED UPS/MFS
Favorite
P 44
TUMOR RESPONSE AND REGROWTH IN RELATION TO CLINICAL EVENTS AMONG PEXIDARTINIB-TREATED SUBJECTS IN THE PHASE 3 ENLIVEN TRIAL
Favorite
P 180
TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY
Favorite
